Thymidine phosphorylase: A potential new target for treating cardiovascular disease.

Authors :: Li W
Yue H
Source :: Trends in cardiovascular medicine [Trends Cardiovasc Med] 2018 Apr; Vol. 28 (3), pp. 157-171. Date of Electronic Publication: 2017 Oct 20.
Publication Year :: 2018
Abstract: We recently found that thymidine phosphorylase (TYMP), also known as platelet-derived endothelial cell growth factor, plays an important role in platelet activation in vitro and thrombosis in vivo by participating in multiple signaling pathways. Platelets are a major source of TYMP. Since platelet-mediated clot formation is a key event in several fatal diseases, such as myocardial infarction, stroke and pulmonary embolism, understanding TYMP in depth may lead to uncovering novel mechanisms in the development of cardiovascular diseases. Targeting TYMP may become a novel therapeutic for cardiovascular disorders. In this review article, we summarize the discovery of TYMP and the potential molecular mechanisms of TYMP involved in the development of various diseases, especially cardiovascular diseases. We also offer insights regarding future studies exploring the role of TYMP in the development of cardiovascular disease as well as in therapy.<br /> (Copyright © 2018 Elsevier Inc. All rights reserved.)

Subjects :: Animals
Cardiovascular Agents adverse effects
Cardiovascular Diseases enzymology
Cardiovascular Diseases genetics
Enzyme Inhibitors adverse effects
Gene Expression Regulation, Enzymologic
Humans
Molecular Targeted Therapy adverse effects
Protein Conformation
Structure-Activity Relationship
Thymidine Phosphorylase chemistry
Thymidine Phosphorylase genetics
Thymidine Phosphorylase metabolism
Cardiovascular Agents therapeutic use
Cardiovascular Diseases drug therapy
Drug Discovery methods
Enzyme Inhibitors therapeutic use
Molecular Targeted Therapy methods
Thymidine Phosphorylase antagonists & inhibitors

Full Text Access

Tools